OBJECTIVE: Although increased oxidative stress and inflammation are highly prevalent in chronic kidney disease (CKD), few studies have investigated whether oral antioxidant therapy can alter markers of inflammation or oxidative stress in patients with CKD. The purpose of this study was to investigate whether a combination of mixed tocopherols and alpha lipoic acid (ALA) would alter biomarkers of oxidative stress and inflammation in subjects with stage 3 to 4 CKD. METHODS: This was a prospective, randomized, double-blind, placebo-controlled pilot trial. In all, 62 subjects were enrolled and were randomly assigned to receive a combination of mixed tocopherols 666 IU/day, in addition to ALA 600 mg/day, or their matching placebos for a total of 8 weeks. Plasma F(2)-isoprostane and protein thiol concentration were measured as biomarkers of oxidative stress, and C-reactive protein and interleukin-6 concentration as biomarkers of systemic inflammation. RESULTS: There were no significant differences in demographics, diabetic status, or estimated glomerular filtration rate between study treatment and placebo groups at baseline. Of the 62 randomized subjects, 58 (93%) completed the study protocol. After 2 months of treatment, there were no significant changes in the concentrations of F(2)-isoprostanes, protein thiols, C-reactive protein, and interleukin-6 with respect to treatment with mixed tocopherols and ALA as compared with matching placebos, whether analyzed as intention to treat or as treated. Diabetic status and baseline body mass index did not influence the results. CONCLUSIONS: Combination of oral mixed tocopherols and ALA treatment for 2 months does not influence biomarkers of oxidative stress and inflammation in patients with stage 3 to 4 CKD.
RCT Entities:
OBJECTIVE: Although increased oxidative stress and inflammation are highly prevalent in chronic kidney disease (CKD), few studies have investigated whether oral antioxidant therapy can alter markers of inflammation or oxidative stress in patients with CKD. The purpose of this study was to investigate whether a combination of mixed tocopherols and alpha lipoic acid (ALA) would alter biomarkers of oxidative stress and inflammation in subjects with stage 3 to 4 CKD. METHODS: This was a prospective, randomized, double-blind, placebo-controlled pilot trial. In all, 62 subjects were enrolled and were randomly assigned to receive a combination of mixed tocopherols 666 IU/day, in addition to ALA 600 mg/day, or their matching placebos for a total of 8 weeks. Plasma F(2)-isoprostane and protein thiol concentration were measured as biomarkers of oxidative stress, and C-reactive protein and interleukin-6 concentration as biomarkers of systemic inflammation. RESULTS: There were no significant differences in demographics, diabetic status, or estimated glomerular filtration rate between study treatment and placebo groups at baseline. Of the 62 randomized subjects, 58 (93%) completed the study protocol. After 2 months of treatment, there were no significant changes in the concentrations of F(2)-isoprostanes, protein thiols, C-reactive protein, and interleukin-6 with respect to treatment with mixed tocopherols and ALA as compared with matching placebos, whether analyzed as intention to treat or as treated. Diabetic status and baseline body mass index did not influence the results. CONCLUSIONS: Combination of oral mixed tocopherols and ALA treatment for 2 months does not influence biomarkers of oxidative stress and inflammation in patients with stage 3 to 4 CKD.
Authors: Eva Lonn; Salim Yusuf; Byrcon Hoogwerf; Janice Pogue; Qilong Yi; Bernard Zinman; Jackie Bosch; Gilles Dagenais; Johannes F E Mann; Hertzel C Gerstein Journal: Diabetes Care Date: 2002-11 Impact factor: 19.112
Authors: E Lonn; S Yusuf; V Dzavik; C Doris; Q Yi; S Smith; A Moore-Cox; J Bosch; W Riley; K Teo Journal: Circulation Date: 2001-02-20 Impact factor: 29.690
Authors: Jonathan Himmelfarb; Jane Kane; Ellen McMonagle; Eric Zaltas; Steve Bobzin; Sekhar Boddupalli; Stephen Phinney; Guy Miller Journal: Kidney Int Date: 2003-09 Impact factor: 10.612
Authors: B Payson Oberg; Elizabeth McMenamin; F Lee Lucas; Ellen McMonagle; Jason Morrow; T Alp Ikizler; Jonathan Himmelfarb Journal: Kidney Int Date: 2004-03 Impact factor: 10.612
Authors: T A Ikizler; J D Morrow; L J Roberts; J A Evanson; B Becker; R M Hakim; Y Shyr; J Himmelfarb Journal: Clin Nephrol Date: 2002-09 Impact factor: 0.975
Authors: V Mohammadi; M Khalili; S Eghtesadi; S Dehghani; S Jazayeri; S K Aghababaee; H Sabour; H Saberi; M Eghtesadi; M R Gohari Journal: Spinal Cord Date: 2015-03-10 Impact factor: 2.772
Authors: T Alp Ikizler; Cassianne Robinson-Cohen; Charles Ellis; Samuel A E Headley; Katherine Tuttle; Richard J Wood; Elizabeth Elspeth Evans; Charles M Milch; Kelsey Anne Moody; Michael Germain; Chutatip Limkunakul; Aihua Bian; Thomas G Stewart; Jonathan Himmelfarb Journal: J Am Soc Nephrol Date: 2017-10-16 Impact factor: 10.121
Authors: Giovanni Pagano; Annarita Aiello Talamanca; Giuseppe Castello; Mario D Cordero; Marco d'Ischia; Maria Nicola Gadaleta; Federico V Pallardó; Sandra Petrović; Luca Tiano; Adriana Zatterale Journal: Int J Mol Sci Date: 2014-11-05 Impact factor: 5.923
Authors: Konstantina P Poulianiti; Antonia Kaltsatou; Georgia I Mitrou; Athanasios Z Jamurtas; Yiannis Koutedakis; Maria Maridaki; Ioannis Stefanidis; Giorgos K Sakkas; Christina Karatzaferi Journal: Oxid Med Cell Longev Date: 2016-08-03 Impact factor: 6.543